Search the Newsreel

BioLife $1.5B buyout to expand Repligen Corporation (NASDAQ: RGEN) platform

Repligen Corporation reported strong Q2 2026 revenue of $204.1 million, an 11.9% increase from Q2 2025, with first-half revenue reaching $398.4 million. The company announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to expand its cell therapy capabilities. This …

ARGX|argenx SE|Price:861.810|Chg%:-20.750

This article provides a comprehensive stock analysis of argenx SE (ARGX), highlighting its relatively stable fundamentals, good growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a "Buy" rating from multiple analysts, with an expected …

Telecom Argentina Number of Employees 2026 | Employee Count & Headcount Data

Telecom Argentina SA reported a total of 19,948 employees worldwide as of March 2026, marking a 3.2% decline from 2023. Despite the overall reduction in headcount, the company is actively hiring, with 88 active job postings in 2026, a 60.7% increase from the previous …

Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up

Repligen (RGEN) reported strong second-quarter 202

Why Repligen (RGEN) Stock Is Up Today

Shares of Repligen Corporation (NASDAQ: RGEN) rose significantly after the biopharma manufacturing company reported strong second-quarter results, beating analyst expectations for both adjusted earnings and revenue. The company also raised its full-year guidance, signaling confidence in its continued performance. This positive news contrasts with …

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has argenex SE (ARGX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the …

Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier

Repligen is highlighted as a leading provider of bioprocessing solutions for biologic drug manufacturers. The company offers a range of advanced systems including filtration, fluid management, chromatography columns, and process analytics. Despite its relatively small size, Repligen is noted for its innovation and record …

Canaccord reiterates Hold on Repligen stock, keeps $145 target

Canaccord Genuity has reiterated a Hold rating on Repligen Corp. (NASDAQ:RGEN) and maintained its $145 price target, believing the shares are fairly valued. The bioprocessing company exceeded analyst expectations for its second-quarter 2026 results, reporting strong revenue growth across all franchises and raising its …

Emergent BioSolutions Inc (EBS) Institutional Confidence

Emergent BioSolutions Inc (EBS) has an institutional shareholding score of 7.00, placing it 50th out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 81.98%, a slight decrease quarter-over-quarter. James Simons is the largest institutional shareholder, with other significant holders including BlackRock …

Banco Bilbao Vizcaya Argentaria SA (BBVA) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Banco Bilbao Vizcaya Argentaria SA's (BBVA) financial health, noting its current financial score of 5.70, ranking 317 out of 394 in the Banking Services industry. The bank's financial status is described as stable, though its operating efficiency is …

TEO|Telecom Argentina SA|Price:13.610|Chg%:-0.370

Telecom Argentina SA (TEO) currently trades at $13.615, showing a slight daily gain and significant year-to-date and annual increases. Despite strong fundamentals and high institutional ownership, the company recently turned to a loss, and analysts currently rate the stock as "Hold" with a target …

argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks

The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking. As leading pharmaceutical companies prepare for a $300 billion patent cliff in the second half of the decade, capital allocation has switched sharply …

Emergent Biosolutions (EBS) Projected to Post Earnings on Wednesday

Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which …

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Corporation reported strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase. The company also announced a definitive agreement to acquire BioLife Solutions, aiming to enhance its cell therapy leadership. Following these positive outcomes, Repligen raised its full-year …

Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Emergent BioSolutions Inc (EBS), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that EBS has a price momentum score of 3.62, trading between a resistance of 8.22 and support …

Emergent BioSolutions | SCHEDULE 13G/A: Others

This article is a SCHEDULE 13G/A filing related to Emergent BioSolutions. It indicates an amendment to a previous filing, typically involving changes in beneficial ownership of the company's stock by a significant investor.

Forgent Power Solutions, Inc. Revenue Breakdown – NYSE:FPS

The article details the revenue breakdown for Forgent Power Solutions, Inc. (NYSE:FPS), highlighting that the United States was its largest contributor, generating $753.19 million USD last year. This figure represents a significant increase from the previous year's $181.31 million USD from the same region. …

Repligen Corporation Stock 12‑Month Price Target Raised to $180.33, Implies 38% Upside

Analysts have raised Repligen Corporation's average 12-month price target to $180.33, up from $176.28. This new target suggests a potential upside of approximately 38% from its July 27 closing price. The consensus rating for RGEN remains a "Buy" among 22 analysts.

Banco BBVA Argentina Number of Employees 2026 | Employee Count & Headcount Data

Repligen (RGEN) Held An M&A Call With BioLife Solutions.

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy …

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Omeros (OMER)

Healthcare analysts have provided insights on Argenx Se (ARGX) and Omeros (OMER). Evercore ISI maintained a Buy rating on Argenx Se with a $1059.00 price target, while Needham maintained a Hold rating on Omeros. Both companies have analyst consensus ratings, with Argenx Se rated …

LAR Maintained by Scotiabank -- Price Target Lowered to $10.00

Scotiabank has maintained its "Sector Outperform" rating for Lithium Argentina (LAR), though it lowered the price target from $11.00 to $10.00. Despite a low GF Score™ of 33/100, indicating below-average performance, the stock shows strong momentum. Investors are advised to proceed with caution due …

Repligen Stock Rises As $1.5B BioLife Deal Targets EPS Boost

Repligen Corporation's stock rose significantly after announcing a $1.5 billion cash-and-stock deal to acquire BioLife Solutions. This acquisition aims to boost Repligen's EPS, adjusted margins, and revenue growth by expanding its bioprocessing footprint into the rapidly growing cell and gene therapy market with BioLife's …

Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat

Repligen (NASDAQ:RGEN) reported a significant earnings beat for Q2 2026, with non-GAAP EPS of $0.54 against an analyst consensus of $0.46, despite revenue being marginally below expectations. The stock surged over 75% in pre-market trading, recouping recent losses, as investors prioritized profitability improvements. The …

Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript

Repligen Corp announced strong Q2 2026 earnings, with 12% reported growth and 13% organic growth, leading to a raised full-year guidance for organic revenue and adjusted EPS. The company saw robust performance in proteins and analytics, with significant growth in APAC and emerging biotech. …

Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates

Repligen (RGEN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Repligen Corp Bottom Line Declines In Q2

(RTTNews) - Repligen Corp (RGEN) announced a profit for second quarter that Drops, from last year The company's bottom line totaled $5.01 million, or $0.09 per share. This compares with $14.87 million, or $0.26 per share, last year. Excluding items, Repligen Corp reported adjusted …

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026 Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 11.9% year on year to $204.1 million. The company expects the full year's revenue to be around …

Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance

Repligen Corporation announced strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase and 13% organic growth. Due to this performance and continued order momentum, the company has raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and …

Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance

Repligen reported strong second-quarter 2026 results with revenue of $204.1 million, a 12% year-over-year increase, and adjusted diluted EPS of $0.54. The company has raised its full-year 2026 guidance for organic revenue growth and adjusted diluted EPS, driven by continued order momentum and portfolio …

argenx (ENXTBR:ARGX) Could Be 15% Above Fair Value On The Forte Deal

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx (ENXTBR:ARGX) is back in focus after agreeing to acquire Forte Biosciences in an all cash deal valued at about US$2.2b, centered on Forte's …

argenx signs agreement to buy Forte Biosciences for $2.2bn

argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset …

argenx (ENXTBR:ARGX) Stock Looks Fairly Valued With Modest Upside On Earnings

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx stock has delivered a very strong 202.6% return over the past five years, yet its current valuation checks point to a more mixed …

Telecom Argentina SA Revenue Breakdown – NYSE:TEO

Lithium Argentina (LAR) Falls 4.7% as Lithium Sector Faces Renewed Pressure - Breakaway Gap